Braveheart Bio, Inc. (BRVE) – What Are Brokerages Thinking About This Stock?

Braveheart Bio, Inc. (NASDAQ:BRVE) has received a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $45.25.

Several analysts recently issued reports on the stock. Jefferies Financial Group initiated coverage on shares of Braveheart Bio in a research note on Monday, August 31st. They set a “buy” rating and a $48.00 price objective for the company. The Goldman Sachs Group assumed coverage on Braveheart Bio in a research report on Monday, August 31st. They issued a “buy” rating and a $48.00 price target for the company. TD Cowen started coverage on Braveheart Bio in a report on Monday, August 31st. They issued a “buy” rating for the company. Wall Street Zen upgraded Braveheart Bio to a “hold” rating in a research report on Saturday, August 15th. Finally, Cantor Fitzgerald initiated coverage on Braveheart Bio in a research note on Monday, August 31st. They set an “overweight” rating and a $40.00 price objective on the stock.

Braveheart Bio Stock Performance

Shares of BRVE opened at $19.21 on Tuesday. Braveheart Bio has a 52-week low of $17.86 and a 52-week high of $32.00. The firm has a market cap of $1.73 billion and a PE ratio of -7.65. The business’s fifty day simple moving average is $24.50.

Braveheart Bio (NASDAQ:BRVE) last issued its earnings results on Tuesday, September 8th. The company reported ($2.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($2.26). On average, sell-side analysts predict that Braveheart Bio will post -1.48 EPS for the current year.

Insider Buying and Selling at Braveheart Bio

In other news, major shareholder Bio Fund Iv L.P. Ah acquired 1,100,000 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was purchased at an average price of $18.00 per share, with a total value of $19,800,000.00. Following the completion of the acquisition, the insider owned 10,232,420 shares of the company’s stock, valued at $184,183,560. This trade represents a 12.05% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Christopher Viehbacher acquired 83,333 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was purchased at an average cost of $18.00 per share, with a total value of $1,499,994.00. Following the acquisition, the director directly owned 609,519 shares of the company’s stock, valued at $10,971,342. This trade represents a 15.84% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have bought 8,751,942 shares of company stock worth $157,534,956.

Braveheart Bio Company Profile

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.